Physician profile
John Stewart
NPI 1447745831
$9,553.43
in general payments reported to CMS, 2019-2025
59 companies · $1,723 in 2025
The $1,723 reported for 2025 was more than what 92% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $721 · 2022: $2,553 · 2023: $2,111 · 2024: $2,447 · 2025: $1,723.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,265 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $14.86.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,264.93 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $14.86 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $995.87 | 2022-2025 | Vraylar, Qulipta, Ubrelvy |
| Pfizer INC. | $979.04 | 2021-2025 | |
| Amgen INC. | $603.25 | 2021-2025 | Repatha, Repatha, Evenity |
| Novo Nordisk INC | $603.06 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $586.18 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Astrazeneca Pharmaceuticals LP | $438.89 | 2021-2025 | Farxiga, Breztri, Airsupra |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $429.54 | 2021-2025 | Xifaxan |
| Exact Sciences Corporation | $373.80 | 2023-2025 | Cologuard Collection Kit |
| Boehringer Ingelheim Pharmaceuticals, INC. | $342.48 | 2021-2025 | Jardiance |
| Dexcom, INC. | $329.65 | 2024-2025 | Dexcom G6 Transmitter |
| Biohaven Pharmaceutical Holding Company LTD. | $303.99 | 2022 | |
| Glaxosmithkline, LLC. | $257.76 | 2022-2025 | Shingrix, Arexvy, Trelegy Ellipta |
| Kowa Pharmaceuticals America, INC. | $244.65 | 2023-2024 | Livalo, Seglentis |
| Amarin Pharma, INC. | $224.46 | 2021-2022 | |
| Supernus Pharmaceuticals, INC. | $202.86 | 2022-2023 | Qelbree, Xyosted |
Show all 59 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Stewart listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.